ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021

IPA to host an earnings conference call via webcast on July 28, 2021, after the close of market

Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform

The collaboration provides greater access to solutions that empower scientists to pursue life-changing medicines.

Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction

IPA announces optimization results of TATX-03 cocktail components designed to improve clinical suitability of their PolyTope therapy

Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event

TATX-21, a novel potential first-in-class antibody for Atherosclerosis Cardiovascular Disease (ACVD).

ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche

Since 2019, Dr. Ilse Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee and has been instrumental in leading IPA’s SARS-CoV-2 Polytope™ Cocktail program

Items 1 to 6 of 145 total

Show per page